Bio-Bridge Science Signs Cooperative Agreement with Chinese Academy of Medical Sciences for Vaccine Development
March 09 2007 - 8:49AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB: BGES) announced today that it has
entered into a cooperative agreement with the Institute of Basic
Medical Sciences at the Chinese Academy of Medical Sciences, a
leading medical research institute in China, to research and
develop a human papillomavirus polyvalent vaccine using prokaryotic
expression system. This vaccine is designed to prevent from
infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and
58, which is expected to provide broader protection than the
current vaccine in the market and have much lower production costs.
Under the agreement, Bio-Bridge has been granted the preferential
right to develop the vaccine and enjoys a 60% interest in the
project. Dr. Liang Qiao, Chairman and CEO of Bio-Bridge said, "We
believe that our agreement with the Chinese Academy of Medical
Sciences will enable us to solidify our research capability in
China as we try to introduce more potential vaccine products in
addition to our current vaccine pipeline. The Chinese Academy of
Medical Sciences is a renowned medical research institute and is
the national level medical science research center in China. We
believe this cooperation will provide numerous benefits to both
parties.� About Chinese Academy of Medical Sciences The Chinese
Academy of Medical Sciences was established in 1956 and is the
national level medical science research center in China. Its former
name was Peking Union Medical College, founded by the Rockefeller
Foundation in 1917. The Academy has 49 doctorate disciplines and 52
master disciplines, 4 national level laboratories, 8 minister level
laboratories and 6 post-doctor WHO research centers. Forward
Looking Statements: This press release contains forward-looking
statements as defined by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements
concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that
are other than statements of historical facts. These statements are
subject to uncertainties and risks including, but not limited to,
product and service demand and acceptance, changes in technology,
economic conditions, the impact of competition and pricing,
government regulation, and other risks defined in this document and
in statements filed from time to time with the Securities and
Exchange Commission. All such forward-looking statements, whether
written or oral, and whether made by or on behalf of the company,
are expressly qualified by these cautionary statements and any
other cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or
circumstances after the date hereof. Please refer to SEC filings
for additional information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bio Bridge Science Inc (CE) (OTCMarkets): 0 recent articles
More Bio-Bridge Science, Inc. News Articles